Laboratory of Experimental Medicine
Head: Marián Hajdúch
Olomouc node
HOME INSTITUTION
Faculty of Medicine PU in Olomouc
RESEARCH PROGRAMME(S)
RP 2 - Research and development of anticancer pharmaceuticals and therapeutic methods
Our group is one of the pioneers of personalized medicine in the Czech Republic. We focus on the molecular essence of human diseases, especially cancer. We are dedicated to the identification and description of metabolic and signaling pathways, genetic and epigenetic changes causing human cancer. This includes tumors of various origins and tumor predisposition, including infectious or inflammatory diseases. The obtained results generate new therapeutically usable molecular targets and biomarkers for the diagnosis and targeted treatment of diseases.
In the field of drug research and development, the group focuses mainly on anticancer drugs from the group of low-molecular chemical compounds and natural substances. We test the biological activity of synthesized chemical compounds, in the case of biologically active substances, we identify the mechanisms of action through the methods of chemical proteomics and genetics. In the case of known molecular targets, we perform high-throughput screening and look for pharmacological inhibitors or activators of the biological activity of the target structure or phenotype. In the next part, we focus in cooperation with medicinal chemists on optimizing the effectiveness and pharmacological properties of candidate molecules. Promising compounds go further into pre-clinical testing and possibly also into verification clinical evaluations.
SELECTED PUBLICATIONS
- Yang C, Slavětínská LP, Fleuti M, Klepetářová B, Tichý M, Gurská S, Pavliš P, Džubák P, Hajdúch M, Hocek M. Synthesis of Polycyclic Hetero-Fused 7-Deazapurine Heterocycles and Nucleosides through C-H Dibenzothiophenation and Negishi Coupling. J Am Chem Soc. 2022 Oct 26;144(42):19437-19446. DOI: 10.1021/jacs.2c07517
- Reissig F, Zarschler K, Novy Z, Petrik M, Bendova K, Kurfurstova D, Bouchal J, Ludik MC, Brandt F, Kopka K, Khoylou M, Pietzsch HJ, Hajduch M, Mamat C. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin. Theranostics. 2022 Oct 17;12(17):7203-7215. DOI: 10.7150/thno.78043
- Kvakova K, Ondra M, Schimer J, Petrik M, Novy Z, Raabova H, Hajduch M, Cigler P. Visualization of Sentinel Lymph Nodes with Mannosylated Fluorescent Nanodiamonds. Adv Funct Mater. 2022;32:2109960. DOI: 10.1002/adfm.202109960
- Grüner B, Brynda J, Das V, Šícha V, Štěpánková J, Nekvinda J, Holub J, Pospíšilová K, Fábry M, Pachl P, Král V, Kugler M, Mašek V, Medvedíková M, Matějková S, Nová A, Lišková B, Gurská S, Džubák P, Hajdúch M, Řezáčová P. Metallacarborane Sulfamides: Unconventional, Specific, and Highly Selective Inhibitors of Carbonic Anhydrase IX. J Med Chem. 2019 Nov 14;62(21):9560-9575. DOI: 10.1021/acs.jmedchem.9b00945
- Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature. 2017 Dec 14;552(7684):194-199. DOI: 10.1038/nature25016